Escalating and sustained immunovirological dissociation among antiretroviral drug-experienced perinatally human immunodeficiency virus-1-infected children and adolescents living in the Central African Republic
暂无分享,去创建一个
C. Charpentier | H. Péré | L. Bélec | J. D. D. Longo | G. Grésenguet | M. Jenabian | J. F. Djoba Siawaya | R. Mboumba Bouassa | M. Matta | J. Gody | C. D. Mossoro-Kpinde | S. Moussa | Mohammad-Ali Jenabian | Ralph-Sydney Mboumba Bouassa | C. Mossoro-Kpinde
[1] C. Charpentier,et al. High predictive efficacy of integrase strand transfer inhibitors in perinatally HIV-1-infected African children in therapeutic failure of first- and second-line antiretroviral drug regimens recommended by the WHO , 2019, The Journal of antimicrobial chemotherapy.
[2] HIV DIAGNOSIS AND ARV USE IN HIV-EXPOSED INFANTS : A PROGRAMMATIC UPDATE JULY 2018 , 2018 .
[3] L. Bélec,et al. High levels of virological failure with major genotypic resistance mutations in HIV-1-infected children after 5 years of care according to WHO-recommended 1st-line and 2nd-line antiretroviral regimens in the Central African Republic , 2017, Medicine.
[4] Manuel Battegay,et al. Development of HIV drug resistance and therapeutic failure in children and adolescents in rural Tanzania: an emerging public health concern , 2016, AIDS.
[5] L. Bélec,et al. Analytical Performances of Human Immunodeficiency Virus Type 1 RNA-Based Amplix® Real-Time PCR Platform for HIV-1 RNA Quantification , 2016, AIDS research and treatment.
[6] L. Bélec,et al. Performance evaluation of the touchscreen-based Muse™ Auto CD4/CD4% single-platform system for CD4 T cell numeration in absolute number and in percentage using blood samples from children and adult patients living in the Central African Republic , 2016, Journal of Translational Medicine.
[7] M. Peeters,et al. High Rates of Drug Resistance Among Newly Diagnosed HIV-infected Children in the National Prevention of Mother-to-child Transmission Program in Togo , 2016, The Pediatric infectious disease journal.
[8] P. Garner,et al. Discordant Immune Response with Antiretroviral Therapy in HIV-1: A Systematic Review of Clinical Outcomes , 2016, PloS one.
[9] M. Peeters,et al. High rates of virological failure and drug resistance in perinatally HIV-1-infected children and adolescents receiving lifelong antiretroviral therapy in routine clinics in Togo , 2016, Journal of the International AIDS Society.
[10] L. Renner,et al. Viral load monitoring and antiretroviral treatment outcomes in a pediatric HIV cohort in Ghana , 2015, BMC Infectious Diseases.
[11] L. Bélec,et al. Tackling virological failure in HIV-infected children living in Africa , 2015, Expert review of anti-infective therapy.
[12] L. Chatenoud,et al. Risk of Severe Non AIDS Events Is Increased among Patients Unable to Increase their CD4+ T-Cell Counts >200+/μl Despite Effective HAART , 2015, PloS one.
[13] M. Egger,et al. Viral load versus CD4+ monitoring and 5-year outcomes of antiretroviral therapy in HIV-positive children in Southern Africa: a cohort-based modelling study , 2014, AIDS.
[14] M. Lederman,et al. Inflammatory cytokines drive CD4+ T-cell cycling and impaired responsiveness to interleukin 7: implications for immune failure in HIV disease. , 2014, The Journal of infectious diseases.
[15] M. Lederman,et al. HIV-Infected Individuals with Low CD4/CD8 Ratio despite Effective Antiretroviral Therapy Exhibit Altered T Cell Subsets, Heightened CD8+ T Cell Activation, and Increased Risk of Non-AIDS Morbidity and Mortality , 2014, PLoS pathogens.
[16] M. Lederman,et al. Dynamics of Immune Reconstitution and Activation Markers in HIV+ Treatment-Naïve Patients Treated with Raltegravir, Tenofovir Disoproxil Fumarate and Emtricitabine , 2013, PloS one.
[17] L. Renner,et al. Effectiveness of first-line antiretroviral therapy and correlates of longitudinal changes in CD4 and viral load among HIV-infected children in Ghana , 2013, BMC Infectious Diseases.
[18] B. Gazzard,et al. The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[19] J. van Lunzen,et al. Prevalence and Determinants of Virological Failure in HIV-Infected Children on Antiretroviral Therapy in Rural Cameroon: A Cross-Sectional Study , 2013, Antiviral therapy.
[20] A. Wensing,et al. Sustained Virological Response on Second-Line Antiretroviral Therapy following Virological Failure in HIV-Infected Patients in Rural South Africa , 2013, PloS one.
[21] J. Overbaugh,et al. Long-Term Virologic Response and Genotypic Resistance Mutations in HIV-1 Infected Kenyan Children on Combination Antiretroviral Therapy , 2013, Journal of acquired immune deficiency syndromes.
[22] C. Charpentier,et al. High rate of antiretroviral drug resistance mutations in HIV type 1-infected Senegalese children in virological failure on first-line treatment according to the World Health Organization guidelines. , 2012, AIDS research and human retroviruses.
[23] M. Fowler,et al. The long-term effectiveness of generic adult fixed-dose combination antiretroviral therapy for HIV-infected Ugandan children. , 2013, African health sciences.
[24] F. Mbopi-Kéou,et al. HIV epidemic out of control in Central African Republic , 2012, The Lancet.
[25] A. Green. The Central African Republic's silent health crisis , 2012, The Lancet.
[26] P. Palma,et al. Suboptimal Immune Reconstitution in Vertically HIV Infected Children: A View on How HIV Replication and Timing of HAART Initiation Can Impact on T and B-cell Compartment , 2012, Clinical & developmental immunology.
[27] F. Mbopi-Kéou,et al. Validation of a Single-Platform, Volumetric, CD45-Assisted PanLeucogating Auto40 Flow Cytometer To Determine the Absolute Number and Percentages of CD4 T Cells in Resource-Constrained Settings Using Cameroonian Patients' Samples , 2012, Clinical and Vaccine Immunology.
[28] C. Charpentier,et al. Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: a cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. , 2012, AIDS research and human retroviruses.
[29] L. Bélec,et al. Challenges in implementing HIV laboratory monitoring in resource-constrained settings: how to do more with less. , 2011, Future microbiology.
[30] Jeffrey N. Martin,et al. Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy , 2011, AIDS.
[31] J. Xie,et al. Reduced thymic output is a major mechanism of immune reconstitution failure in HIV-infected patients after long-term antiretroviral therapy. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[32] T. R. D. de Wit,et al. HIV-1-resistance-associated mutations after failure of first-line antiretroviral treatment among children in resource-poor regions: a systematic review. , 2011, The Lancet. Infectious diseases.
[33] C. Rouzioux,et al. Immunovirological response to combined antiretroviral therapy and drug resistance patterns in children: 1- and 2-year outcomes in rural Uganda , 2011, BMC pediatrics.
[34] F. Mascart,et al. Cellular immune responses in human immunodeficiency virus (HIV)‐1‐infected children: is immune restoration by highly active anti‐retroviral therapy comparable to non‐progression? , 2011, Clinical and experimental immunology.
[35] A. Wensing,et al. Long-term Outcome of Children Receiving Antiretroviral Treatment in Rural South Africa: Substantial Virologic Failure on First-line Treatment , 2011, The Pediatric infectious disease journal.
[36] R. Barth,et al. Long-Term Outcome of an HIV-Treatment Programme in Rural Africa: Viral Suppression despite Early Mortality , 2010, AIDS research and treatment.
[37] G. Bren,et al. Patients with Discordant Responses to Antiretroviral Therapy Have Impaired Killing of HIV-Infected T Cells , 2010, PLoS pathogens.
[38] J. Crump,et al. Predicting Virologic Failure Among HIV-1-Infected Children Receiving Antiretroviral Therapy in Tanzania: a Cross-Sectional Study , 2010, Journal of acquired immune deficiency syndromes.
[39] S. G. Gundersen,et al. Drug resistance is widespread among children who receive long-term antiretroviral treatment at a rural Tanzanian hospital , 2010, The Journal of antimicrobial chemotherapy.
[40] M. Clerici,et al. CD4+ T Cell Depletion, Immune Activation and Increased Production of Regulatory T Cells in the Thymus of HIV-Infected Individuals , 2010, PloS one.
[41] A. Breckenridge,et al. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial , 2010, The Lancet.
[42] C. Yiannoutsos,et al. Mortality Associated With Discordant Responses to Antiretroviral Therapy in Resource-Constrained Settings , 2010, Journal of acquired immune deficiency syndromes.
[43] V. Calvez,et al. Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali. , 2010, The Journal of antimicrobial chemotherapy.
[44] M. Egger,et al. Outcomes of the South African National Antiretroviral Treatment Programme for children: the IeDEA Southern Africa collaboration. , 2009, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.
[45] J. V. van Oosterhout,et al. Diagnosis of antiretroviral therapy failure in Malawi: poor performance of clinical and immunological WHO criteria , 2009, Tropical medicine & international health : TM & IH.
[46] J. Hogan,et al. Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[47] J. Ananworanich,et al. Pattern and Predictors of Immunologic Recovery in Human Immunodeficiency Virus-Infected Children Receiving Non-Nucleoside Reverse Transcriptase Inhibitor-Based Highly Active Antiretroviral Therapy , 2009, The Pediatric infectious disease journal.
[48] T. Quinn,et al. Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda , 2009, AIDS.
[49] S. Lawn,et al. Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa , 2009, AIDS.
[50] C. Charpentier,et al. High prevalence of antiretroviral drug resistance mutations in HIV-1 non-B subtype strains from African children receiving antiretroviral therapy regimen according to the 2006 revised WHO recommendations. , 2008, Journal of acquired immune deficiency syndromes.
[51] Lewis H Kuller,et al. Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV Infection , 2008, PLoS medicine.
[52] M. Nolan,et al. Virologic and immunologic response to antiretroviral therapy and predictors of HIV type 1 drug resistance in children receiving treatment in Abidjan, Côte d'Ivoire. , 2008, AIDS research and human retroviruses.
[53] F. Miedema,et al. Restoration of the CD4 T Cell Compartment after Long-Term Highly Active Antiretroviral Therapy without Phenotypical Signs of Accelerated Immunological Aging1 , 2008, The Journal of Immunology.
[54] J. Martinez-Picado,et al. HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo. , 2008, Virus research.
[55] T. Quinn,et al. Predictors of Long-Term Viral Failure Among Ugandan Children and Adults Treated With Antiretroviral Therapy , 2007, Journal of acquired immune deficiency syndromes.
[56] J. Overbaugh,et al. Early Response to Highly Active Antiretroviral Therapy in HIV-1-Infected Kenyan Children , 2007, Journal of acquired immune deficiency syndromes.
[57] R. Zachariah,et al. Treatment outcomes stratified by baseline immunological status among young children receiving nonnucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in resource-limited settings. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[58] Sarah C Leeper,et al. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa , 2007, BMC pediatrics.
[59] C. Rouzioux,et al. Long-term survival and immuno-virological response of African HIV-1-infected children to highly active antiretroviral therapy regimens , 2006, AIDS.
[60] R. Cheynier,et al. Naïve T-Cell Depletion Related to Infection by X4 Human Immunodeficiency Virus Type 1 in Poor Immunological Responders to Highly Active Antiretroviral Therapy , 2006, Journal of Virology.
[61] M. Hirsch,et al. Effect of Baseline- and Treatment-Related Factors on Immunologic Recovery After Initiation of Antiretroviral Therapy in HIV-1-Positive Subjects: Results From ACTG 384 , 2006, Journal of acquired immune deficiency syndromes.
[62] F. van Leth,et al. Long-term Experience With Combination Antiretroviral Therapy That Contains Nelfinavir for up to 7 Years in a Pediatric Cohort , 2006, Pediatrics.
[63] C. Rouzioux,et al. Genotypic Human Immunodeficiency Virus Type 1 Drug Resistance in Highly Active Antiretroviral Therapy-Treated Children in Abidjan, Côte d'Ivoire , 2005, The Pediatric infectious disease journal.
[64] B. Clotet,et al. HIV type 1 fitness evolution in antiretroviral-experienced patients with sustained CD4+ T cell counts but persistent virologic failure. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[65] M. Schutten,et al. Sustained viral suppression and immune recovery in HIV type 1-infected children after 4 years of highly active antiretroviral therapy. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[66] M. Muñoz-Fernández,et al. Impact of highly active antiretroviral therapy on CD4+ T cells and viral load of children with AIDS: a population-based study. , 2004, AIDS research and human retroviruses.
[67] Nigel Rollins,et al. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis , 2004, The Lancet.
[68] S. Blanche,et al. Highly active antiretroviral therapies among HIV-1-infected children in Abidjan, Côte d'Ivoire , 2004, AIDS.
[69] A. De Rossi. Virological and immunological response to antiretroviral therapy in HIV-1 infected children: genotypic and phenotypic assays in monitoring virological failure. , 2004, The new microbiologica.
[70] Kent J Weinhold,et al. Prolonged CD4+ cell/virus load discordance during treatment with protease inhibitor-based highly active antiretroviral therapy: immune response and viral control. , 2003, The Journal of infectious diseases.
[71] N. Klein,et al. Increased thymic output after initiation of antiretroviral therapy in human immunodeficiency virus type 1-infected children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 Trial. , 2002, The Journal of infectious diseases.
[72] C. Giaquinto,et al. Immune reconstitution in HIV-1-infected children on antiretroviral therapy: role of thymic output and viral fitness , 2002, AIDS.
[73] R. de Groot,et al. Efficacy of highly active antiretroviral therapy in HIV-1 infected children. , 2002, The Lancet. Infectious diseases.
[74] T. Wrin,et al. CD4+ T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy. , 2002, The Journal of infectious diseases.
[75] Jeffrey N. Martin,et al. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia , 2002, AIDS.
[76] S. Pahwa,et al. Evaluation of T cell receptor gene rearrangement excision circles after antiretroviral therapy in children infected with human immunodeficiency virus. , 2001, The Journal of infectious diseases.
[77] M. Kazatchkine,et al. Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen. , 2001, The Journal of infectious diseases.
[78] V. Trouplin,et al. Retracing the Evolutionary Pathways of Human Immunodeficiency Virus Type 1 Resistance to Protease Inhibitors: Virus Fitness in the Absence and in the Presence of Drug , 2000, Journal of Virology.
[79] M. Kazatchkine,et al. High levels of drug-resistant human immunodeficiency virus variants in patients exhibiting increasing CD4+ T cell counts despite virologic failure of protease inhibitor-containing antiretroviral combination therapy. , 2000, The Journal of infectious diseases.
[80] M. Ascher,et al. Dissociation of Immunologic and Virologic Responses to Highly Active Antiretroviral Therapy , 2000, Journal of acquired immune deficiency syndromes.
[81] J L Sullivan,et al. Effect of HIV on thymic function before and after antiretroviral therapy in children. , 2000, The Journal of infectious diseases.
[82] Richard A. Loftus,et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. , 1999, AIDS.
[83] F. Mammano,et al. Resistance-Associated Loss of Viral Fitness in Human Immunodeficiency Virus Type 1: Phenotypic Analysis of Protease andgag Coevolution in Protease Inhibitor-Treated Patients , 1998, Journal of Virology.
[84] F. Mammano,et al. Loss of Viral Fitness Associated with Multiple Gag and Gag-Pol Processing Defects in Human Immunodeficiency Virus Type 1 Variants Selected for Resistance to Protease Inhibitors In Vivo , 1998, Journal of Virology.